Compare iShares MSCI Hong Kong ETF (EWH) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 14.6× iShares MSCI Hong Kong ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EWH | ZBH | |
|---|---|---|
Market Cap | $1.16B | $16.95B |
Volume | 3,176,523 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $103.98 |
52-Week Low | $20.66 | $79.58 |
Typical Hold Time | 61 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $21.72 with a 0.65% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Moving averages signal strong bearish momentum while oscillators remain neutral. Recent institutional selling includes Empowered Funds LLC reducing its position by 70.2% in Q2 2026.
Outlook remains cautious given Hong Kong market volatility and geopolitical risks. The ETF's performance is tied to Chinese tech stocks and regional economic conditions. Near-term resistance at $22 presents a key level for bullish reversal, but continued pressure on Asian markets suggests limited upside potential without significant catalyst.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
